The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) modakafusp alfa and subasumstat (TAK-981) have obtained tacit clinical trial approvals. The targeted indications are multiple myeloma (MM) and CD20-positive relapsed/refractory non-Hodgkin’s lymphoma (NHL) combined with rituximab, respectively.
TAK-573: A First-in-Class Drug for Relapsed/Refractory MM
TAK-573, a potential first-in-class drug, consists of two attenuated interferon alpha-2b (IFN α2b) molecules genetically fused to the Fc portion of a humanized anti-CD38 IgG4 monoclonal antibody (mAb). This innovative design allows TAK-573 to deliver IFN α2b specifically to CD38-positive cells, thereby regulating the IFNα receptor pathway in patients with relapsed/refractory MM. Nonclinical studies have demonstrated that TAK-573 exhibits potent antitumor activity in a MM xenograft model, capable of inducing complete remission.
TAK-981: A SUMO-Activating Enzyme Inhibitor
TAK-981 is a SUMO-activating enzyme (SAE) inhibitor. SUMOylation is a reversible post-translational modification that modulates protein function through the covalent attachment of small ubiquitin-like modifiers (SUMOs). This process involves a series of enzymatic cascade reactions, including the catalysis of SUMO activating enzymes (SAEs). Previous studies have shown that SUMOylation can inhibit type I interferon (IFN1) signaling. TAK-981 works by blocking the binding of the SAE catalytic site to the substrate, forming a SUMO-TAK-981 complex. This mechanism inhibits the SUMOylation modification process, reactivates IFN1 signaling, and promotes both innate and adaptive immune responses against tumors.-Fineline Info & Tech
